Compare FLYW & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLYW | TSHA |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 2021 | 2020 |
| Metric | FLYW | TSHA |
|---|---|---|
| Price | $14.39 | $5.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 8 |
| Target Price | ★ $16.21 | $11.63 |
| AVG Volume (30 Days) | ★ 2.1M | 2.0M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 450.00 | 5.56 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $623,025,000.00 | $9,773,000.00 |
| Revenue This Year | $19.68 | N/A |
| Revenue Next Year | $15.25 | $1,152.42 |
| P/E Ratio | $145.80 | ★ N/A |
| Revenue Growth | ★ 26.59 | 17.28 |
| 52 Week Low | $10.09 | $2.25 |
| 52 Week High | $18.05 | $7.30 |
| Indicator | FLYW | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 41.40 | 43.87 |
| Support Level | $12.82 | $5.27 |
| Resistance Level | $15.13 | $6.01 |
| Average True Range (ATR) | 0.63 | 0.36 |
| MACD | -0.32 | -0.04 |
| Stochastic Oscillator | 16.22 | 36.78 |
Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements, namely a payments platform, a proprietary payment network, and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.